Symbols

VCEL

Vericel·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VCEL

Vericel Corporation

A leader in advanced therapies for the sports medicine and severe burn care markets

Industry

Biological Technology

Established Date

Listing Date

02/04/1997

Exchange

NASDAQ Stock Exchange

Full-time Employees

398

Fiscal Year Ends

12-31

Website

www.vcel.com

Security Type

Common stock

Office address

64 Sidney Street, Cambridge, MA 02139

Business

Introduction

Vericel Corporation was incorporated in Michigan in March 1989 and began employee operations in 1991. The Company is a fully integrated commercial-stage biopharmaceutical company and a leading provider of advanced therapies for the sports medicine and severe burn care markets. It sells three FDA-approved products in the US: MACI for cartilage repair, Epicel for severe burns, and NexoBrid for thermal burn eschar removal.

Company Financials

EPS

VCEL has released its 2025 Q4 earnings. EPS was reported at 0.45, versus the expected 0.39, beating expectations. The chart below visualizes how VCEL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VCEL has released its 2025 Q4 earnings report, with revenue of 92.92M, reflecting a YoY change of 23.27%, and net profit of 23.24M, showing a YoY change of 17.35%. The Sankey diagram below clearly presents VCEL's revenue sources and cost distribution.